MIM
KLRS

Monashee Investment Management’s Kalaris Therapeutics KLRS Stock Holding History

Monashee Investment Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,304
Closed -$1.27M – 102
2023
Q2 		$1.27M Buy
+16,304
New +$1.55M 0.3% 51

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Monashee Investment Management's KLRS Position: Q3 2023 in Review

Monashee Investment Management sold out of Kalaris Therapeutics (KLRS) in Q3 2023, closing a stake of 16,304 shares — an estimated $1.27M sold.

Monashee Investment Management first reported a position in KLRS in Q2 2023 and held it in 1 quarter. The position peaked at $1.27M in Q2 2023. 90 funds tracked by Wall St. Rank hold KLRS as of Q3 2023.

  • Monashee Investment Management reported no remaining Kalaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Monashee Investment Management sold 16,304 Kalaris Therapeutics shares in Q3 2023, an estimated $1.27M.
  • Monashee Investment Management first reported a position in Kalaris Therapeutics in Q2 2023 and held it in 1 quarter.
  • Monashee Investment Management's Kalaris Therapeutics position peaked at $1.27M in Q2 2023.
  • 90 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2023.

Based on Monashee Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.